Matouš Hrdinka, Ph.D.

Dr. Matouš Hrdinka stands at the forefront of cancer biology and molecular immunology research, focusing on uncovering the intricate mechanisms of ubiquitin and kinase oncogenic signaling and advancing antibody and cell-based immunotherapies. With over a decade of experience in both academic and pharmaceutical sectors, Dr. Hrdinka has distinguished himself as an accomplished senior scientist and a visionary leader in target discovery and validation. As a principal investigator at the University Hospital Ostrava & University of Ostrava, he is instrumental in pioneering preclinical research and advancing our understanding of blood cancer therapies.

His work is characterized by a profound expertise in cancer cell biology, molecular immunology, and the development of cutting-edge immunotherapies. Dr. Hrdinka’s leadership and project management skills are evident in his ability to lead international teams, secure significant research funding, and drive forward innovative cancer therapeutics development. His dedication to bridging the gap between academic research and pharmaceutical advancements is further demonstrated by his active role in fostering academic collaborations.


Cancer Biology, Molecular Immunology, Oncogenic Signaling, Ubiquitin, Kinases, Antibody Therapies, Cell-based Immunotherapies, ADCs, CAR-T, CAR-NK

  • 2006-2012 Ph.D. in Molecular Immunology, Charles University in Prague
  • 2009 Rerum Naturalium Doctor (RNDr.) degree in Molecular Biology and Genetics, Charles University in Prague
  • 2001-2006 Master’s Degree (Mgr.) in Molecular Biology, Charles University in Prague
Eminent awards
  • Postdoctoral Fellowship, Ludwig Institute for Cancer Research, University of Oxford (2013–2017)
Key activities
  • Discovery research in ubiquitin and kinase oncogenic signaling
  • Preclinical Target Discovery & Validation
  • Lecturing and mentoring in Immunology and Cell Biology
  • Evaluation Panel Committee Member, Czech Science Foundation
+420 597 372 065
Scroll to Top